Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Group

Sedef, Ali; Kose, Fatih; Sumbul, Ahmet; Besen, Ali; Hacioglu, Bekir; Gunaldi, Meral; Nayir, Erdinc; TANRIVERDİ, ÖZGÜR; Arpaci, Erkan; Abali, Huseyin; ÖZYILKAN, ÖZGÜR

Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Group

Atıf İçin Kopyala

Sedef A. M. , Kose F., Sumbul A. T. , Besen A. A. , Hacioglu B., Gunaldi M., et al.

JOURNAL OF BUON, cilt.24, ss.650-655, 2019 (SCI İndekslerine Giren Dergi)

Cilt numarası: 24 Konu: 2
Basım Tarihi: 2019
Dergi Adı: JOURNAL OF BUON
Sayfa Sayısı: ss.650-655

Özet

Purpose: Advanced gastric cancer has a dismal prognosis. Platin/5-fluorouracil (PF) combination chemotherapy is the main treatment modality for metastatic gastric cancer patients. Third drug addition to PF is a controversial issue. The aim of this study was to evaluate the predictive role of tumor localization and histopathology on choosing three- or two-drug combination regimens.